Cirrhosis News and Research

Latest Cirrhosis News and Research

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

Study sheds new light on body's immune response to hepatitis A, C viruses

A surprising finding in a study comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees by a team that includes scientists from the Texas Biomedical Research Institute sheds new light on the nature of the body's immune response to these viruses.

21 Jun 2011

Australians getting fatter but living longer and smoking less: Health report card

Experts formulating a report on Australia’s health related figures say that Australian men and women are living longer than ever thanks to a drop in deaths from notorious diseases and cancer, but the rising weight has left the door open to a host of new health problems. The key finding of a major study released today was that excess weight carried by one in four children and more than 60 per cent of adults was contributing to an increase in chronic diseases across the country.

19 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Overweight increases risk of liver cirrhosis in men

Overweight carries a greatly increased risk of cirrhosis of the liver in men, reveals a new study from the Sahlgrenska Academy. "Given the increasing problem of overweight in Sweden, there is reason to fear that more people will develop cirrhosis of the liver," says Jerzy Kaczynski, docent at the University of Gothenburg and doctor at Sahlgrenska University Hospital.

8 Jun 2011

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

The [Ryan] privatization proposal overlooks the fact that when it comes to rising health costs, Medicare is part of the solution, not the problem. ... Together with health care reform, Medicare can be the driver of innovation due to its sheer market share.

6 Jun 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Amylin Pharmaceuticals, Inc. today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy.

6 Jun 2011

Elastography and serum markers show promise in patients with liver disease

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression.

3 Jun 2011

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

2 Jun 2011

Obesity and insulin resistance are a greater risk for fatty liver than previously thought

Being overweight and resistant to insulin constitute a greater risk for fatty liver than was previously thought, according to a study from Linköping University in Sweden that is now being published in the journal Annals of Medicine.

30 May 2011

NovaShunt launches new corporate identity and product branding

NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG it prepares for the upcoming launch of the ALFApump System in Europe.

30 May 2011

Two new hepatitis C drugs effectively improve cure rates of African Americans

Two new drugs just approved by the Food and Drug Administration to treat hepatitis C genotype 1 significantly improved the cure rates of patients. One of the drugs was extremely effective in treating African Americans.

27 May 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine.

25 May 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules, decreasing the effects of inflammation and fibrosis in acute kidney injury.

24 May 2011

Cirrhosis News and Research

Latest Cirrhosis News and Research

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Telaprevir drug shows promise in curing hepatitis C infection

Study sheds new light on body's immune response to hepatitis A, C viruses

Australians getting fatter but living longer and smoking less: Health report card

Galectin strengthens cancer drug patent portfolio in Europe

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Overweight increases risk of liver cirrhosis in men

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Elastography and serum markers show promise in patients with liver disease

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Obesity and insulin resistance are a greater risk for fatty liver than previously thought

NovaShunt launches new corporate identity and product branding

Two new hepatitis C drugs effectively improve cure rates of African Americans

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in